Arctoris Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $4.97M

  • Investors
  • 14

Arctoris General Information

Description

Operator of an automated drug discovery platform intended to streamline the development of new drugs towards the clinic. The company leverages robotics and artificial intelligence to generate superior quality drug discovery data from a wide range of biochemical, cell-based and molecular biology assays conducted by robotics, enabling clients to make rapid decisions based on reliable, structured and well-annotated data, leading to faster and more efficient drug discovery programs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 120 East Olympic Avenue
  • Oxfordshire, Milton Park
  • Abingdon OX14 4SA
  • England, United Kingdom
+44 07713
Primary Industry
Discovery Tools (Healthcare)
Corporate Office
  • 120 East Olympic Avenue
  • Oxfordshire, Milton Park
  • Abingdon OX14 4SA
  • England, United Kingdom
+44 07713

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arctoris Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC 14-Aug-2023 $4.97M Completed Generating Revenue
8. Early Stage VC 19-Nov-2020 Completed Generating Revenue
7. Grant 01-Jun-2020 Completed Generating Revenue
6. Accelerator/Incubator 01-Jan-2020 Completed Generating Revenue
5. Seed Round 01-Jul-2019 Completed Generating Revenue
4. Grant 01-Dec-2018 Completed Generating Revenue
3. Grant 01-Sep-2018 Completed Generating Revenue
2. Seed Round 01-Jun-2018 $861K $861K Completed Generating Revenue
1. Grant 01-Nov-2017 $185K Completed Startup
To view Arctoris’s complete valuation and funding history, request access »

Arctoris Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Seed
Ordinary 321,998 $0.000128 $12.75 $12.75 1x $12.75 16.88%
Ordinary 128,000 $0.000128 $6.41 $6.41 1x $6.41 6.71%
To view Arctoris’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Arctoris Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of an automated drug discovery platform intended to streamline the development of new drugs towards the clinic.
Discovery Tools (Healthcare)
Abingdon, United Kingdom
42 As of 2026

Chesterfield, MO
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Arctoris Competitors (8)

One of Arctoris’s 8 competitors is Partek, a Corporate Backed or Acquired company based in Chesterfield, MO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Partek Corporate Backed or Acquired Chesterfield, MO
Exscientia Formerly VC-backed Oxford, United Kingdom
Dnastar Private Debt Financed Madison, WI
Illumina Formerly VC-backed San Diego, CA
Benchling Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 8 competitors. Get the full list »

Arctoris Patents

Arctoris Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230135701-A1 Drug discovery using a pseudo concentration-response curve Inactive 29-Oct-2021
US-20200199513-A1 System and a method for producing an encapsulated cellular spheroid Inactive 19-Dec-2018
US-20200172843-A1 Apparatus for controlling an experimental temperature of an experimental material Inactive 04-Dec-2018
US-20210147771-A1 Apparatus for controlling an experimental temperature of an experimental material Inactive 04-Dec-2018
CA-3126575-A1 A system and method of performing a biological experiment with adaptive cybernetic control of procedural conditions Active 18-Oct-2018 C12M41/48
To view Arctoris’s complete patent history, request access »

Arctoris Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arctoris Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Formic Ventures Venture Capital Minority
GK Goh Holdings Fund of Funds Minority
UK Innovation Agency Government Minority
Creative Destruction Lab Accelerator/Incubator
Acequia Capital Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

Arctoris Investments (1)

Arctoris’s most recent deal was a Corporate Asset Purchase with Eli Lilly (Life Sciences Studio in San Diego, California). The deal was made on 12-Sep-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Eli Lilly (Life Sciences Studio in San Diego, California) 12-Sep-2024 Corporate Asset Purchase Buildings and Property
To view Arctoris’s complete investments history, request access »

Arctoris FAQs

  • When was Arctoris founded?

    Arctoris was founded in 2016.

  • Where is Arctoris headquartered?

    Arctoris is headquartered in Abingdon, United Kingdom.

  • What is the size of Arctoris?

    Arctoris has 42 total employees.

  • What industry is Arctoris in?

    Arctoris’s primary industry is Discovery Tools (Healthcare).

  • Is Arctoris a private or public company?

    Arctoris is a Private company.

  • What is the current valuation of Arctoris?

    The current valuation of Arctoris is .

  • What is Arctoris’s current revenue?

    The current revenue for Arctoris is .

  • How much funding has Arctoris raised over time?

    Arctoris has raised $16.4M.

  • Who are Arctoris’s investors?

    Formic Ventures, GK Goh Holdings, UK Innovation Agency, Creative Destruction Lab, and Acequia Capital are 5 of 14 investors who have invested in Arctoris.

  • Who are Arctoris’s competitors?

    Partek, Exscientia, Dnastar, Illumina, and Benchling are some of the 8 competitors of Arctoris.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process